Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Jeremy S. Frieling"'
Publikováno v:
Journal of Bone Oncology, Vol 47, Iss , Pp 100610- (2024)
The skeleton is a common site of cancer metastasis and malignancy with the resultant lesions often being incurable. Interactions between metastatic cancer cells and the bone microenvironment are critical for cancer cell survival, outgrowth, and progr
Externí odkaz:
https://doaj.org/article/55f3ce97c0354f99ad047eaedeaa7b4f
Autor:
Ryan T. Bishop, Anna K. Miller, Matthew Froid, Niveditha Nerlakanti, Tao Li, Jeremy S. Frieling, Mostafa M. Nasr, Karl J. Nyman, Praneeth R. Sudalagunta, Rafael R. Canevarolo, Ariosto Siqueira Silva, Kenneth H. Shain, Conor C. Lynch, David Basanta
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Multiple myeloma (MM) is an osteolytic malignancy that is incurable due to the emergence of treatment resistant disease. Defining how, when and where myeloma cell intrinsic and extrinsic bone microenvironmental mechanisms cause relapse is ch
Externí odkaz:
https://doaj.org/article/6a891d57aa954ccea72f58bdbad908a5
Autor:
Jeremy J. McGuire, Jeremy S. Frieling, Chen Hao Lo, Tao Li, Ayaz Muhammad, Harshani R. Lawrence, Nicholas J. Lawrence, Leah M. Cook, Conor C. Lynch
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
The effects of bone-marrow derived MSCs on prostate cancer cells remain unknown. Here the authors show that MSC-derived IL-28 induces prostate cancer cell apoptosis via IL-28Rα-STAT1 signalling, while acquired resistance to apoptosis is associated w
Externí odkaz:
https://doaj.org/article/61b815bbfbe3485cb1696124b372aa50
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 22, Iss 10, Pp 511-521 (2020)
Bone metastatic prostate cancer significantly impacts patient quality of life and overall survival, and despite available therapies, it is presently incurable with an unmet need for improved treatment options. As mediators of tumor progression, matri
Externí odkaz:
https://doaj.org/article/3b58597b6f904a0e96ae10553b709124
Autor:
Jeremy S. Frieling, Leticia Tordesillas, Xiomar E. Bustos, Maria Cecilia Ramello, Ryan T. Bishop, Junior E. Cianne, Sebastian A. Snedal, Tao Li, Chen Hao Lo, Janis de la Iglesia, Emiliano Roselli, Ismahène Benzaïd, Xuefeng Wang, Youngchul Kim, Conor C. Lynch, Daniel Abate-Daga
Publikováno v:
Science Advances. 9
Immune checkpoint blockade has been largely unsuccessful for the treatment of bone metastatic castrate-resistant prostate cancer (mCRPC). Here, we report a combinatorial strategy to treat mCRPC using γδ-enriched chimeric antigen receptor (CAR) T ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f40a9b602316ea315f33d27e79a0861f
https://doi.org/10.1126/sciadv.adf0108
https://doi.org/10.1126/sciadv.adf0108
Autor:
Leticia Tordesillas, Junior Cianne, Jeremy S. Frieling, Xiomar Bustos, Conor C. Lynch, Daniel Abate-Daga
Publikováno v:
Cancer Research. 83:1767-1767
Background: Metastatic castrate resistant prostate cancer (mCRPC) is frequently manifested in the bone, leading to increased morbidity and mortality. We have previously demonstrated that γδ Chimeric Antigen Receptor (CAR) T cells targeting prostate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef50b3c1ffcc5548547cdaae6eeca127
https://doi.org/10.1158/1538-7445.am2023-1767
https://doi.org/10.1158/1538-7445.am2023-1767
Autor:
Catherine S. Johnson, Diane Costanzo-Garvey, Massar Alsamraae, Jeremy S. Frieling, Leah M. Cook
Publikováno v:
Cancer Research. 83:82-82
In 2022, the American Cancer Society estimates that over 34,000 men will die of PCa, largely due to metastatic PCa. Up to 90% of advanced prostate cancers metastasize to bone, and there are currently no curative therapies for bone metastatic prostate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::885eb5e7b691b341b586e7c4dd3ea620
https://doi.org/10.1158/1538-7445.am2023-82
https://doi.org/10.1158/1538-7445.am2023-82
Autor:
Jeremy S. Frieling, Xiomar Bustos, Ryan T. Bishop, Leticia Tordesillas, Daniel Abate-Daga, Conor C. Lynch
Publikováno v:
Cancer Research. 83:3992-3992
Bone metastatic castrate resistant prostate cancer (CRPC) generates tumors hallmarked by extensive bone formation due to enhanced mesenchymal stem cell (MSC)-osteoblast differentiation. These lesions are at present incurable and substantially diminis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::152b1e7bbda2b45d6ffb1ca2189785cc
https://doi.org/10.1158/1538-7445.am2023-3992
https://doi.org/10.1158/1538-7445.am2023-3992
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 22, Iss 10, Pp 511-521 (2020)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
Bone metastatic prostate cancer significantly impacts patient quality of life and overall survival, and despite available therapies, it is presently incurable with an unmet need for improved treatment options. As mediators of tumor progression, matri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dcb799cc74b4d3d79e144122a692e09
https://doi.org/10.1016/j.neo.2020.08.004
https://doi.org/10.1016/j.neo.2020.08.004
Autor:
Tammy Kielian, Adam J. Case, Leah M. Cook, Yangsheng Yu, Massar Alsamraae, Cortney E. Heim, Tyler Keeley, Diane L. Costanzo-Garvey, Jeremy S. Frieling, Kaihong Su, Gabrielle F. Watson, Colm Morrissey
Publikováno v:
Cancer Immunology, Immunotherapy
Bone metastatic prostate cancer (BM-PCa) significantly reduces overall patient survival and is currently incurable. Current standard immunotherapy showed promising results for PCa patients with metastatic, but less advanced, disease (i.e., fewer than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef7eef9991098f146f3caf71a92ebc72
https://doi.org/10.1007/s00262-020-02527-6
https://doi.org/10.1007/s00262-020-02527-6